In Vitro Toxicity Testing: Technologies and Global Markets

Published - Jan 2014| Analyst - Robert Hunter| Code - PHM017E
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

The global in vitro toxicity testing market was valued at $4 billion in 2011 and more than $4.9 billion in 2012. This market is estimated to reach nearly $9.9 billion in 2017, with a compound annual growth rate (CAGR) of 14.7% for the five-year period, 2012 to 2017.

Report Includes

  • An overview of the global in vitro toxicity testing market, with assessments of its growth potential over the next five years and the current market scenario for alternative measures to animal testing.
  • Analyses of market trends, with data from 2011 and 2012, and projections of CAGRs for the period 2012 and 2017.
  • Discussion of the two major technology-based approaches, mechanistic and nonmechanistic.
  • A breakdown of influential factors, such as validation of the alternative measures for toxicity and toxicity testing strategies for chemicals, pesticides, and food additives.
  • Profiles of major players in the industry


The scope of the report encompasses the major types of traditional toxicity testing that have been used, and the in vitro techniques that are being developed by industry, government agencies and nonprofits. It analyzes current market status, examines drivers on future markets and presents forecasts of growth over the next five years.

Technology developments, including the latest trends, are discussed. Other influential factors such as validation and testing strategies for pharmaceuticals, cosmetics, and chemicals have also been included.

Regulatory drivers play a large role in toxicology, determining the specific parameters of tests that have been explicitly required. They also heavily influence the testing that is performed by companies in earlier stages of research. The report examines the regulatory role and the different federal and international agencies that play an active role in in vitro toxicology research, development and adoption.

The term ‘predictive’ is often used in conjunction with in vitro toxicology, and historically predictive approaches (also called ‘nonmechanistic’) have been contrasted with mechanistic approaches. This report does discuss where applicable the relative magnitude of the two. However, our research shows that increasingly the two are used in tandem, and that they are being viewed as complementary parts of an overall toolkit. Thus, our use of the term ‘Predictive Toxicology’ as a subject/discipline throughout is intended to encompass both predictive and mechanistic, and to connote an evolution of the overall toolkit. In keeping with the ‘Tox 21’ vision detailed later, the key attribute of this overall evolution is being more and more able to use in vitro methods to predict in vivo outcomes.

Relative to the pharmaceutical industry, this report covers the testing of pharmaceutical or so-called ‘small molecule’ drugs, synthesized from chemical compounds. Biologics, so-called ‘large molecule’ drugs, are tested via completely different approaches and technologies. Biologics safety testing is outside the scope of this report.

Analyst Credentials

Robert Hunter is a senior management consultant, commercialization consultant and technology and market analyst with over 20 years of experience in life sciences and healthcare. Recent consulting includes market/technology analysis and forecasting of customer adoption and revenue for a high content screening (HCS) technology leader. He is an early investor in a company using stem cells for predictive drug safety testing in vitro. He has a B.S. in Mechanical Engineering from Clemson University and Master of Business Administration from The Tuck School of Business at Dartmouth.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Sep-2010| Analyst - Paul Evers| Code - PHM017D

Report Highlights

  • The global in vitro toxicity (predictive toxicity) testing market is valued at more than $1.3 billion in 2010.  With heightened awareness of animal welfare in laboratory research testing, the in vitro toxicity testing market has an anticipated value of $2.7 billion in 2015, a compound annual growth rate (CAGR) of 15% between 2010 and 2015.
  • The largest market sector is currently the cosmetics and personal-care industry, which accounts for a market share of more than 50%. This sector is currently valued at $702 million and is expected to reach $1.3 billion by 2015, a compound annual growth rate (CAGR) of 13.1%.
  • The pharmaceuticals segment is one of the most significant with a 32% market share valued at $424 million in 2010. By 2015, this sector is projected to reach a value of $976 million, a compound annual growth rate (CAGR) of 18.2%.
Published - Mar-2007| Analyst - Vanita Khetan| Code - PHM017C

Report Highlights

  • The U.S. in vitro toxicity (predictive toxicity) testing market has been valued at $765 million in 2006. At a compound annual growth rate (CAGR) of 14.4%, the total U.S. market will grow to reach $1.5 billion by 2011.
  • Mechanistic toxicology testing had the highest growth through the forecast period, with an estimated CAGR of 21.8%. This sector of the market will be worth $720 million by 2011.
  • Non-mechanistic toxicology testing was the larger of the two sectors in 2006. Even with a CAGR of 9.4%, it will still maintain the majority of the market at $780 million in 2011.
Published - Jun-2003| Analyst - Sam Brauer| Code - PHM017B

Report Highlights

  • The pharmaceutical industry accounts for more than 90% of the industry.
  • In vitro toxicology growth (12.4%/year) will be higher than pharmaceutical R& D.
  • The pharmaceutical market will reach about $18.58 billion by 2007.
  • All other markets will grow 8%/year to reach $103 milion.
  • Overall, in vitro toxicology markets will see an AAGR of 12.1%.


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report